Abstract
Hepatitis C virus (HCV), the major etiological agent of transfusion-associated non-A, non-B hepatitis, is a severe health problem affecting up to 3% of the world population. Since its identification in 1989, enormous efforts have been made to characterize the viral cycle. However, many details regarding the virus penetration of hepatocytes, its replication and translation, and the assembling of virions remain unknown, mostly because of a lack of an efficient culture system. This has also hampered the development of fully effective antiviral drugs. Current treatments based on the combination of interferon and ribavirin trigger a sustained virological response in only 40% of infected individuals, thus the development of alternative therapeutic strategies is a major research goal. Nucleic acid based therapeutic agents may be of some potential in hepatitis C treatment. In recent years, much effort has gone into the improvement of DNA and RNA molecules as specific gene silencing tools. This review summarizes the state of the art in the development of new HCV therapies, paying special attention to those involving antisense oligonucleotides, aptamers, ribozymes, decoys and siRNA inhibitors. The identification of potential viral targets is also discussed.
Keywords: HCV, hepatitis C, gene silencing, RNA-based inhibitors, ribozyme, antisense, aptamer, siRNA
Infectious Disorders - Drug Targets
Title: Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids
Volume: 6 Issue: 2
Author(s): C. Romero-Lopez, F. J. Sanchez-Luque and A. Berzal-Herranz
Affiliation:
Keywords: HCV, hepatitis C, gene silencing, RNA-based inhibitors, ribozyme, antisense, aptamer, siRNA
Abstract: Hepatitis C virus (HCV), the major etiological agent of transfusion-associated non-A, non-B hepatitis, is a severe health problem affecting up to 3% of the world population. Since its identification in 1989, enormous efforts have been made to characterize the viral cycle. However, many details regarding the virus penetration of hepatocytes, its replication and translation, and the assembling of virions remain unknown, mostly because of a lack of an efficient culture system. This has also hampered the development of fully effective antiviral drugs. Current treatments based on the combination of interferon and ribavirin trigger a sustained virological response in only 40% of infected individuals, thus the development of alternative therapeutic strategies is a major research goal. Nucleic acid based therapeutic agents may be of some potential in hepatitis C treatment. In recent years, much effort has gone into the improvement of DNA and RNA molecules as specific gene silencing tools. This review summarizes the state of the art in the development of new HCV therapies, paying special attention to those involving antisense oligonucleotides, aptamers, ribozymes, decoys and siRNA inhibitors. The identification of potential viral targets is also discussed.
Export Options
About this article
Cite this article as:
Romero-Lopez C., Sanchez-Luque J. F. and Berzal-Herranz A., Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112182
DOI https://dx.doi.org/10.2174/187152606784112182 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry From Cocaine to Ropivacaine: The History of Local Anesthetic Drugs
Current Topics in Medicinal Chemistry An Overview of Olive Oil Biomolecules
Current Biotechnology Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology The Use of Major Analgesics in Patients with Renal Dysfunction
Current Drug Targets Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Evidence that Cortical Dopamine is a Co-Transmitter in Noradrenergic Neurons
Current Psychiatry Reviews Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry